Sunwin International Neutraceuticals, Inc. Realizes 22% Revenue Increase in the Second Quarter

FORT LAUDERDALE, FL -- (MARKET WIRE) -- 01/17/2005 -- Sunwin International Neutraceuticals, Inc. (OTC BB: SUWN), an industry leader in Chinese herbs, veterinary medicines and low calorie natural sweetener (Stevioside) in China, reported today results for the second quarter ending October 31, 2004.

Revenue for the second quarter of 2005's fiscal year increased 22% to US $3,159,151, compared to US $2,583,680 in the second quarter of fiscal year 2004. Gross profit for the first quarter is US $901,469, compared to US $860,452 for the period ending October 31, 2003. However, net income for the first quarter of 2005 decreased to US $63,030, compared to net income of US $254,809 in the second quarter of 2004, due to a non-cash compensation charge for the merger. Shareholder equity increased 6.1% to US $4,247,344 for the period ending October 31, 2004, compared to US $4,096,814 for the period ending July 31, 2004.

Revenue for the first six months of 2005's fiscal year increased 24% to US $6,458,285, compared to US $5,217,643 in the first six months of fiscal year 2004. Gross profit for the six months is US $1,950,690, compared to US $1,708,085 in the same period ending October 31, 2003. However, net income for the first six months of fiscal year of 2005 decreased to US $159,389, compared to net income of US $470,164 in the first six months of fiscal year of 2004, due to a non-cash compensation charge for the merger.

The Company's President, Laiwang Zhang, noted, "We are pleased with our financial results. Our revenue growth for the quarter was attributable to the growing demand for our natural sweetener, Stevioside. We continue to achieve substantial growth in our core business revenues, while improving our gross profitability and strengthening our balance sheet. Given our ability to access the US capital markets, management believes we can improve our financial performance. We are poised to continue and accelerate our growth."

About Sunwin International Neutraceuticals, Inc.

Sunwin International Neutraceuticals, Inc. ("Sunwin") is engaged in the areas of essential traditional Chinese medicine, 100% organic herbal medicine, neutraceutical products, natural sweetener (Stevioside), and animal medicine prepared from 100% organic herbal ingredients. As an industry leader in agricultural processing, Sunwin has built an integrated global firm with the sourcing and production capabilities to meet the needs of consumers throughout the world. Sunwin also makes such value-added products as specialty veterinary food ingredients and specialty feed ingredients. The Sunwin family works closely with consumers to provide quality, value, and a hybrid mix of agricultural products and services that meet growing demand. In 2002, Sunwin was recognized as one of the first 2,000 state-level companies that China authorized as the most important innovative high-tech pioneer businesses by the Chinese central government. In 2002, Sunwin was awarded as one of 2002's state-level biological product manufacturers in China. In 2003, Sunwin ranked as one of the top 50 companies of China's Animal Related Health Care Product Pharmaceutical Industry. In 2003, Sunwin received an award as one of Shandong's Top-Ten Innovative, High-Tech Businesses by the Province Government of Shandong. For more information about Sunwin, please visit http://www.sunwin.biz

Safe Harbor Statement

Certain of the statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish